Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

[1]  O. Levran,et al.  CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction , 2013, Addiction biology.

[2]  J. Brockmöller,et al.  Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function , 2013, Molecular Psychiatry.

[3]  Su-Jun Lee,et al.  Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine , 2013, Front. Gene..

[4]  D. Rozman,et al.  Molecular Interactions between NAFLD and Xenobiotic Metabolism , 2013, Front. Gene..

[5]  H. Brauch,et al.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M Schwab,et al.  Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver , 2011, The Pharmacogenomics Journal.

[7]  J. Stockman.  Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis , 2013 .

[8]  Genome-wide association study reveals a complex genetic architecture underpinning-induced CYP3A4 enzyme activity , 2013, European Journal of Drug Metabolism and Pharmacokinetics.

[9]  Marylyn D Ritchie,et al.  Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants , 2012, Pharmacogenetics and genomics.

[10]  M. Turpeinen,et al.  Cytochrome P450 2B6: function, genetics, and clinical relevance , 2012, Drug metabolism and drug interactions.

[11]  W. Haefeli,et al.  High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study , 2011, The Pharmacogenomics Journal.

[12]  Lang Li,et al.  Impact of the Interaction between 3′-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes , 2012, Front. Gene..

[13]  Juxiang Yuan,et al.  CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studies , 2012, BMC Cancer.

[14]  Tai-ping He,et al.  Association of CYP1A1 polymorphisms with prostate cancer risk: an updated meta-analysis , 2012, Molecular Biology Reports.

[15]  N. Helsby,et al.  Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19 , 2012, Front. Gene..

[16]  W. Sadee.  The Relevance of “Missing Heritability ” in Pharmacogenomics , 2012, Clinical pharmacology and therapeutics.

[17]  Yusuke Nakamura,et al.  Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. , 2012, Journal of the National Cancer Institute.

[18]  V. Stanton.  Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. , 2012, Journal of the National Cancer Institute.

[19]  C. Caldas,et al.  Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.

[20]  D. Kim,et al.  Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. , 2012, The American journal of cardiology.

[21]  G. Koren,et al.  Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. , 2012, Current drug metabolism.

[22]  F. Innocenti,et al.  Liver expression quantitative trait loci: a foundation for pharmacogenomic research , 2012, Front. Gene..

[23]  M. Niemi,et al.  PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo , 2012, Clinical pharmacology and therapeutics.

[24]  H. Raunio,et al.  CYP2A6: genetics, structure, regulation, and function , 2012, Drug metabolism and drug interactions.

[25]  A. Wikman,et al.  Metabolism of bilirubin by human cytochrome P450 2A6. , 2012, Toxicology and applied pharmacology.

[26]  Andrew A Somogyi,et al.  Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. , 2012, British journal of clinical pharmacology.

[27]  A. Henney,et al.  The virtual liver: a multidisciplinary, multilevel challenge for systems biology , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.

[28]  H. Baelde,et al.  CYP3A5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP3A5 in the Proximal Tubule in Carriers of the CYP3A5*1 Allele , 2012, Drug Metabolism and Disposition.

[29]  M. Stoneking,et al.  Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. , 2012, Pharmacogenomics.

[30]  J. Cuzick,et al.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.

[31]  P. Neven,et al.  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. , 2012, Journal of the National Cancer Institute.

[32]  U. Zanger,et al.  Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism. , 2012, Toxicology.

[33]  J E Lunshof,et al.  Pharmacogenomic Testing: Knowing More, Doing Better , 2012, Clinical pharmacology and therapeutics.

[34]  H. Brauch,et al.  Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. , 2012, Human molecular genetics.

[35]  N. Helsby,et al.  Which CYP2B6 Variants Have Functional Consequences for Cyclophosphamide Bioactivation? , 2012, Drug Metabolism and Disposition.

[36]  D. Mansuy,et al.  Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. , 2012, Chemical research in toxicology.

[37]  Joseph K. Pickrell,et al.  A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes , 2012, Science.

[38]  Z. Dong,et al.  Association of the CYP1B1 Leu432Val polymorphism with the risk of prostate cancer: a meta-analysis , 2012, Molecular Biology Reports.

[39]  J. Cornuz,et al.  Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking , 2012, Pharmacogenetics and genomics.

[40]  K. Makar,et al.  Potential Contribution of Cytochrome P450 2B6 to Hepatic 4-Hydroxycyclophosphamide Formation In Vitro and In Vivo , 2012, Drug Metabolism and Disposition.

[41]  Tetsuya Terasaki,et al.  Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities , 2012, Drug Metabolism and Disposition.

[42]  Marylyn D. Ritchie,et al.  The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients , 2012, Pharmacogenetics and genomics.

[43]  N. Djebli,et al.  Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite , 2012, Drug Metabolism and Disposition.

[44]  Greyson Twist,et al.  CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. , 2012, Pharmacogenomics.

[45]  T. Lesnick,et al.  Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. , 2012, Leukemia research.

[46]  Ulrich M. Zanger,et al.  Metabolism of drugs and other xenobiotics , 2012 .

[47]  K. Jain.  Applications of AmpliChip™ CYP450 , 2012, Molecular Diagnosis.

[48]  Yusuke Nakamura,et al.  CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans , 2011, European Journal of Clinical Pharmacology.

[49]  Michael V Holmes,et al.  CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. , 2011, JAMA.

[50]  J. Halpert,et al.  The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4. , 2011, Biochemistry.

[51]  A. Hofman,et al.  Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study , 2011, Pharmacogenetics and genomics.

[52]  R. Tyndale,et al.  Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. , 2011, Trends in pharmacological sciences.

[53]  J. Halpert,et al.  Structures of Cytochrome P450 2B6 Bound to 4-Benzylpyridine and 4-(4-Nitrobenzyl)pyridine: Insight into Inhibitor Binding and Rearrangement of Active Site Side Chains , 2011, Molecular Pharmacology.

[54]  Jing Yuan,et al.  Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine , 2011, Pharmacogenetics and genomics.

[55]  B. Fromenty,et al.  Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity , 2011, The FEBS journal.

[56]  Takuya Kumamoto,et al.  Q172H Replacement Overcomes Effects on the Metabolism of Cyclophosphamide and Efavirenz Caused by CYP2B6 Variant with Arg262 , 2011, Drug Metabolism and Disposition.

[57]  Lang Li,et al.  Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age , 2011, Clinical pharmacology and therapeutics.

[58]  V. Haufroid,et al.  A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.

[59]  V. Haufroid,et al.  Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. , 2011, Pharmacogenomics.

[60]  M. Hiratsuka,et al.  Functional Characterization of CYP2B6 Allelic Variants in Demethylation of Antimalarial Artemether , 2011, Drug Metabolism and Disposition.

[61]  B. Fromenty,et al.  Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. , 2011, Clinics and research in hepatology and gastroenterology.

[62]  D. Billheimer,et al.  Analysis of Global and Absorption, Distribution, Metabolism, and Elimination Gene Expression in the Progressive Stages of Human Nonalcoholic Fatty Liver Disease , 2011, Drug Metabolism and Disposition.

[63]  C. Thangavel,et al.  Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men. , 2011, Endocrinology.

[64]  Warfarin pharmacogenetics meets clinical use , 2011, Blood.

[65]  Paul Flicek,et al.  The functional spectrum of low-frequency coding variation , 2011, Genome Biology.

[66]  M. Spitz,et al.  Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. , 2011, Journal of the National Cancer Institute.

[67]  F. Guengerich,et al.  Orphans in the Human Cytochrome P450 Superfamily: Approaches to Discovering Functions and Relevance in Pharmacology , 2011, Pharmacological Reviews.

[68]  K. Verbeke,et al.  In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine‐Treated as Compared With Tacrolimus‐Treated Renal Allograft Recipients , 2011, Clinical pharmacology and therapeutics.

[69]  T. Harrer,et al.  Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. , 2011, The Journal of antimicrobial chemotherapy.

[70]  Andreas Zell,et al.  Inferring statin-induced gene regulatory relationships in primary human hepatocytes , 2011, Bioinform..

[71]  R. Zemni,et al.  Role of CYP1A1 (T6235C) polymorphism and cigarette smoking in the development of coronary heart disease in Tunisian population , 2011, Journal of Genetics.

[72]  J. Ibrahim,et al.  Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  V. Manolopoulos,et al.  Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. , 2011, Pharmacogenomics.

[74]  D. Waxman,et al.  Transcriptional Profiling of Human Liver Identifies Sex-Biased Genes Associated with Polygenic Dyslipidemia and Coronary Artery Disease , 2011, PloS one.

[75]  W. Sadee,et al.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.

[76]  H. Inoko,et al.  Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients , 2011, Bone Marrow Transplantation.

[77]  Xin A. Zhang,et al.  The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. , 2011, Advanced drug delivery reviews.

[78]  U. Zanger,et al.  MIRNA-DISTILLER: A Stand-Alone Application to Compile microRNA Data from Databases , 2011, Front. Gene..

[79]  M. Ingelman-Sundberg,et al.  The Ligands of Estrogen Receptor α Regulate Cytochrome P4502C9 (CYP2C9) Expression , 2011, Journal of Pharmacology and Experimental Therapeutics.

[80]  J. Cornuz,et al.  Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility , 2011, Clinical pharmacology and therapeutics.

[81]  A. Figueiras,et al.  Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review , 2011, Pharmacogenetics and genomics.

[82]  R. Brugada,et al.  Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel , 2011, Heart.

[83]  Gerd Mikus,et al.  Pharmacogenomics of the triazole antifungal agent voriconazole. , 2011, Pharmacogenomics.

[84]  D. Podzamczer,et al.  Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent , 2011, AIDS.

[85]  B. Giusti,et al.  Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis , 2011, The Pharmacogenomics Journal.

[86]  R. Mägi,et al.  Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. , 2011, Human molecular genetics.

[87]  T. Fehm,et al.  Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma , 2011, Clinical pharmacology and therapeutics.

[88]  L. Natarajan,et al.  Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes , 2011, Clinical pharmacology and therapeutics.

[89]  Russ B Altman,et al.  PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2. , 2011, Pharmacogenetics and genomics.

[90]  M. Hellmich,et al.  Effect of the CYP2C8 Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide , 2011, Drug Metabolism and Disposition.

[91]  Christopher D. Brown,et al.  Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue , 2011, PLoS genetics.

[92]  W. Leppert.  CYP2D6 in the Metabolism of Opioids for Mild to Moderate Pain , 2011, Pharmacology.

[93]  K. Giacomini,et al.  Consequences of POR mutations and polymorphisms , 2011, Molecular and Cellular Endocrinology.

[94]  W. Vach,et al.  Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer , 2011, The Pharmacogenomics Journal.

[95]  R. Milne,et al.  Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity , 2011, The Pharmacogenomics Journal.

[96]  Eun-Young Kim,et al.  Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo , 2011, Drug Metabolism and Disposition.

[97]  D. Kiel,et al.  Eight Common Genetic Variants Associated with Serum DHEAS Levels Suggest a Key Role in Ageing Mechanisms , 2011, PLoS genetics.

[98]  E. Rimm,et al.  Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24 (CYP1A2) As Determinants of Habitual Caffeine Consumption , 2011, PLoS genetics.

[99]  W. Miller,et al.  Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms. , 2011, Molecular endocrinology.

[100]  Andrew D. Johnson,et al.  Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy , 2011, Clinical pharmacology and therapeutics.

[101]  Wolfgang Weiss,et al.  A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..

[102]  C. Adithan,et al.  Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients , 2011, European Journal of Clinical Pharmacology.

[103]  W. Vach,et al.  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer , 2011, European Journal of Clinical Pharmacology.

[104]  Min Huang,et al.  MicroRNA hsa-miR-613 targets the human LXRα gene and mediates a feedback loop of LXRα autoregulation. , 2011, Molecular endocrinology.

[105]  Vladimir B. Bajic,et al.  dPORE-miRNA: Polymorphic Regulation of MicroRNA Genes , 2011, PloS one.

[106]  L. Bertilsson,et al.  4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. , 2011, British journal of clinical pharmacology.

[107]  H. Bartsch,et al.  Ethanol‐mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA‐lesions , 2011, International journal of cancer.

[108]  Nancy J. Cox,et al.  A Study of CNVs As Trait-Associated Polymorphisms and As Expression Quantitative Trait Loci , 2011, PLoS genetics.

[109]  S-M He,et al.  Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. , 2011, Current medicinal chemistry.

[110]  Matthias Cavassini,et al.  Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. , 2011, The Journal of infectious diseases.

[111]  D. Pounder,et al.  CYP2B6 and OPRM1 gene variations predict methadone‐related deaths , 2011, Addiction biology.

[112]  A. Hofman,et al.  Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes , 2011, Pharmacogenetics and genomics.

[113]  A. Serretti,et al.  Pharmacogenetics of Antidepressants , 2010, Front. Pharmacol..

[114]  Shengying Qin,et al.  A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China. , 2008, Genomics.

[115]  C. Flück,et al.  Clinical and biochemical consequences of p450 oxidoreductase deficiency. , 2011, Endocrine development.

[116]  Michal Otyepka,et al.  Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations. , 2011, Biochimica et biophysica acta.

[117]  Tetsuya Terasaki,et al.  Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. , 2011, Journal of pharmaceutical sciences.

[118]  C. Buechler,et al.  Does hepatic steatosis affect drug metabolizing enzymes in the liver? , 2011, Current drug metabolism.

[119]  Yusuke Nakamura,et al.  Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients , 2011, Breast Cancer Research and Treatment.

[120]  G. Hortobagyi,et al.  Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer , 2010, Clinical Cancer Research.

[121]  J. Turgeon,et al.  Metabolic Activity and mRNA Levels of Human Cardiac CYP450s Involved in Drug Metabolism , 2010, PloS one.

[122]  J. Ritz,et al.  Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation , 2010, American journal of hematology.

[123]  U. Fuhr,et al.  University of Birmingham Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency , 2010 .

[124]  Stephen T. C. Wong,et al.  Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. , 2010, Pharmacogenomics.

[125]  K. Giacomini,et al.  Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro , 2010, Pharmacogenetics and genomics.

[126]  M. Ingelman-Sundberg,et al.  Regulation of CYP2C19 Expression by Estrogen Receptor α: Implications for Estrogen-Dependent Inhibition of Drug Metabolism , 2010, Molecular Pharmacology.

[127]  Mark George Thomas,et al.  CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme , 2010, Pharmacogenetics and genomics.

[128]  Hongbing Wang,et al.  Synergistically Enhanced CYP2B6 Inducibility between a Polymorphic Mutation in CYP2B6 Promoter and Pregnane X Receptor Activation , 2010, Molecular Pharmacology.

[129]  Robert T. Taylor,et al.  Role of Epigenetic Mechanisms in Differential Regulation of the Dioxin-Inducible Human CYP1A1 and CYP1B1 Genes , 2010, Molecular Pharmacology.

[130]  M. Schwab,et al.  Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver , 2010, Front. Pharmacol..

[131]  Ute Hofmann,et al.  Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes , 2010, Drug Metabolism and Disposition.

[132]  D. Clifford,et al.  Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. , 2010, The Journal of infectious diseases.

[133]  Victoria M. Pratt,et al.  Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants , 2010, Front. Pharmacol..

[134]  C. Caldas,et al.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen , 2010, Breast Cancer Research.

[135]  Xia Yang,et al.  Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. , 2010, Genome research.

[136]  Duan Liu,et al.  Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[137]  G. Hankins,et al.  Bupropion metabolism by human placenta. , 2010, Biochemical pharmacology.

[138]  C. Cellier,et al.  CYP2C9*3 Loss‐of‐Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin , 2010, Clinical pharmacology and therapeutics.

[139]  M. Gawaz,et al.  Platelet pharmacogenomics , 2010, Journal of thrombosis and haemostasis : JTH.

[140]  L. Wienkers,et al.  Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation , 2010, Drug Metabolism and Disposition.

[141]  F. Stüber,et al.  Personalized therapy in pain management: where do we stand? , 2010, Pharmacogenomics.

[142]  M. Hiratsuka,et al.  Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2–CYP2B6.28, except CYP2B6.22) , 2010, Pharmacogenetics and genomics.

[143]  C. Gieger,et al.  Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior , 2010, Nature Genetics.

[144]  M. Ingelman-Sundberg,et al.  The past, present and future of pharmacoepigenomics. , 2010, Pharmacogenomics.

[145]  Bo Wang,et al.  Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 , 2010, Drug metabolism reviews.

[146]  S. Janković,et al.  Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 −163C>A polymorphism , 2010, European Journal of Clinical Pharmacology.

[147]  Yasuhiro Aoki,et al.  Human CYP2E1 is regulated by miR-378. , 2010, Biochemical pharmacology.

[148]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II , 2010, Clinical pharmacokinetics.

[149]  Stephanie C Huelga,et al.  Crystal Structure of a Cytochrome P450 2B6 Genetic Variant in Complex with the Inhibitor 4-(4-Chlorophenyl)imidazole at 2.0-Å Resolution , 2010, Molecular Pharmacology.

[150]  B. Wouters,et al.  Diminished Carcinogen Detoxification Is a Novel Mechanism for Hypoxia-inducible Factor 1-mediated Genetic Instability* , 2010, The Journal of Biological Chemistry.

[151]  Yusuke Nakamura,et al.  Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  Y. Hofmann,et al.  New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4 , 2010, Drug Metabolism and Disposition.

[153]  S. Taudien,et al.  The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability , 2010, Pharmacogenetics and genomics.

[154]  S. Strom,et al.  Genetic Predictors of Interindividual Variability in Hepatic CYP3A4 Expression , 2010, Journal of Pharmacology and Experimental Therapeutics.

[155]  J. Lafitte,et al.  Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers. , 2010, Biochimie.

[156]  P. Farndon,et al.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. , 2010, British journal of clinical pharmacology.

[157]  Haiyan Yang,et al.  Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. , 2010, European journal of cancer.

[158]  M. Rieder,et al.  Human Liver Expression of CYP2C8: Gender, Age, and Genotype Effects , 2010, Drug Metabolism and Disposition.

[159]  D Jamieson,et al.  Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide , 2010, British Journal of Cancer.

[160]  D. Trafalis,et al.  CYP2E1 and risk of chemically mediated cancers , 2010, Expert opinion on drug metabolism & toxicology.

[161]  B. Brüne,et al.  MicroRNA-27b Contributes to Lipopolysaccharide-mediated Peroxisome Proliferator-activated Receptor γ (PPARγ) mRNA Destabilization* , 2010, The Journal of Biological Chemistry.

[162]  N. Benowitz,et al.  New CYP2A6 gene deletion and conversion variants in a population of Black African descent. , 2010, Pharmacogenomics.

[163]  N. Vermeulen,et al.  Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression , 2010, The Pharmacogenomics Journal.

[164]  A. Kastrati,et al.  Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.

[165]  Matthias Cavassini,et al.  ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir , 2010, Pharmacogenetics and genomics.

[166]  S. Leucht,et al.  Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome , 2010, The Pharmacogenomics Journal.

[167]  B. Masters,et al.  Human Cytochrome P450 Oxidoreductase Deficiency Caused by the Y181D Mutation: Molecular Consequences and Rescue of Defect , 2010, Drug Metabolism and Disposition.

[168]  Caroline A. Lee,et al.  Identification of Novel Substrates for Human Cytochrome P450 2J2 , 2010, Drug Metabolism and Disposition.

[169]  K. Yoshinari,et al.  Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'-flanking region. , 2010, Biochemical pharmacology.

[170]  Jyh-Chin Yang,et al.  CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection , 2010, Expert opinion on drug metabolism & toxicology.

[171]  J. N. van den Anker,et al.  Efavirenz in the therapy of HIV infection , 2010, Expert opinion on drug metabolism & toxicology.

[172]  M. Perera.  The missing linkage: what pharmacogenetic associations are left to find in CYP3A? , 2010, Expert opinion on drug metabolism & toxicology.

[173]  R. Chakraborty,et al.  Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations , 2010, Human mutation.

[174]  Osamu Okazaki,et al.  Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite , 2010, Drug Metabolism and Disposition.

[175]  F. Baumann,et al.  Gender difference in ifosfamide metabolism by human liver microsomes , 2001, European Journal of Drug Metabolism and Pharmacokinetics.

[176]  J. Dungan,et al.  Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen , 2010 .

[177]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.

[178]  C. Gieger,et al.  Sequence variants at CHRNB 3 – CHRNA 6 and CYP 2 A 6 affect smoking behavior , 2010 .

[179]  T. Sergentanis,et al.  Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis , 2010, Breast Cancer Research and Treatment.

[180]  R. Tyndale,et al.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors , 2010, European Journal of Clinical Pharmacology.

[181]  T. Sergentanis,et al.  Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis , 2010, Breast Cancer Research and Treatment.

[182]  Lei Yao,et al.  Lack of significant association between CYP1A1 T3801C polymorphism and breast cancer risk: a meta-analysis involving 25,087 subjects , 2010, Breast Cancer Research and Treatment.

[183]  Shingo Takagi,et al.  MicroRNAs Regulate Human Hepatocyte Nuclear Factor 4α, Modulating the Expression of Metabolic Enzymes and Cell Cycle* , 2009, The Journal of Biological Chemistry.

[184]  C. Dani,et al.  microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. , 2009, Biochemical and biophysical research communications.

[185]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[186]  P. Kremsner,et al.  Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. , 2009, The Lancet. Infectious diseases.

[187]  U. Fuhr,et al.  The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. , 2009, Basic & clinical pharmacology & toxicology.

[188]  S. Willmann,et al.  Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.

[189]  M. Bochud,et al.  The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test , 2009, Pharmacogenetics and genomics.

[190]  Shu-Feng Zhou,et al.  Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. , 2009, Current drug metabolism.

[191]  T. Kamataki,et al.  Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[192]  T. Warner,et al.  The Epoxygenases CYP2J2 Activates the Nuclear Receptor PPARα In Vitro and In Vivo , 2009, PloS one.

[193]  Dale Hattis,et al.  Genetic Polymorphism in CYP2E1: Population Distribution of CYP2E1 Activity , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.

[194]  S. Bojesen,et al.  Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52 000 individuals , 2009, The Pharmacogenomics Journal.

[195]  M. Pirmohamed.  The applications of pharmacogenetics to prescribing: what is currently practicable? , 2009, Clinical medicine.

[196]  Yuzhuo Pan,et al.  MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material. , 2009, Drug Metabolism and Disposition.

[197]  Fernando Rivadeneira,et al.  A genome-wide association study of acenocoumarol maintenance dosage. , 2009, Human molecular genetics.

[198]  Wei Zhang,et al.  A pharmacogene database enhanced by the 1000 Genomes Project. , 2009, Pharmacogenetics and genomics.

[199]  H. Brauch,et al.  Pharmacogenomics of tamoxifen therapy. , 2009, Clinical chemistry.

[200]  C. Aquilante,et al.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. , 2009, Pharmacogenomics.

[201]  S. Bojesen,et al.  CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50 000 individuals , 2009, Pharmacogenetics and genomics.

[202]  Shu-Feng Zhou,et al.  Structure, function, regulation and polymorphism of human cytochrome P450 2A6. , 2009, Current drug metabolism.

[203]  M. T. Donato,et al.  Cytochrome p450 and steatosis. , 2009, Current drug metabolism.

[204]  Michael Müller,et al.  Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human , 2009, PloS one.

[205]  J. Halperin,et al.  CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. , 2009, Pharmacogenomics.

[206]  Dennis Shasha,et al.  miRò: a miRNA knowledge base , 2009, Database J. Biol. Databases Curation.

[207]  Paolo Palatini,et al.  CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension , 2009, Journal of hypertension.

[208]  C. Eap,et al.  ABCB1 and Cytochrome P450 Polymorphisms: Clinical Pharmacogenetics of Clozapine , 2009, Journal of clinical psychopharmacology.

[209]  H. Bartsch,et al.  Ethanol‐induced cytochrome P4502E1 causes carcinogenic etheno‐DNA lesions in alcoholic liver disease , 2009, Hepatology.

[210]  D. Waxman,et al.  Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes , 2009, Molecular Pharmacology.

[211]  J. Stevens,et al.  Human hepatic CYP2B6 developmental expression: the impact of age and genotype. , 2009, Biochemical pharmacology.

[212]  Daniel E Jonas,et al.  Genetic and clinical factors relating to warfarin dosing. , 2009, Trends in pharmacological sciences.

[213]  M. Ingelman-Sundberg,et al.  Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. , 2009, Pharmacogenetics and genomics.

[214]  M. Ingelman-Sundberg,et al.  Regulation of Human CYP2C18 and CYP2C19 in Transgenic Mice: Influence of Castration, Testosterone, and Growth Hormone , 2009, Drug Metabolism and Disposition.

[215]  M. Loriot,et al.  Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function , 2009, Drug Metabolism and Disposition.

[216]  J. Goldstein,et al.  The transcriptional regulation of the human CYP2C genes. , 2009, Current drug metabolism.

[217]  A. McLachlan,et al.  Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. , 2009, Current drug metabolism.

[218]  Ding Ma,et al.  Selective Inhibitors of CYP2J2 Related to Terfenadine Exhibit Strong Activity against Human Cancers in Vitro and in Vivo , 2009, Journal of Pharmacology and Experimental Therapeutics.

[219]  L. Milani,et al.  Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers , 2009, The Pharmacogenomics Journal.

[220]  M. Moya,et al.  Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. , 2009, Current drug metabolism.

[221]  K. Jamil,et al.  CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis. , 2009, Urology journal.

[222]  U. Hofmann,et al.  A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes , 2009, Drug Metabolism and Disposition.

[223]  M. Youle,et al.  Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population , 2009, HIV medicine.

[224]  Katrin Marcus,et al.  Mass spectrometry‐based absolute quantification of microsomal cytochrome P450 2D6 in human liver , 2009, Proteomics.

[225]  J. Dressman,et al.  Cytochrome P450-mediated metabolism in the human gut wall. , 2009, The Journal of pharmacy and pharmacology.

[226]  A. Telenti,et al.  Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals , 2009, Clinical pharmacology and therapeutics.

[227]  M. Schwab,et al.  Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. , 2009, Pharmacogenomics.

[228]  Jingbo Wang,et al.  Predicting potentially functional SNPs in drug-response genes. , 2009, Pharmacogenomics.

[229]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[230]  Huldrych F. Günthard,et al.  In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function , 2009, Pharmacogenetics and genomics.

[231]  V. Haufroid,et al.  Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.

[232]  T. Eschenhagen,et al.  Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study , 2009, Clinical pharmacology and therapeutics.

[233]  G. Di Fede,et al.  The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density. , 2009, Bone.

[234]  R. Porcher,et al.  Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia , 2009, Leukemia.

[235]  J. Halpert,et al.  Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important Drugs , 2009, Drug Metabolism and Disposition.

[236]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[237]  S. Hercberg,et al.  Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. , 2009, The Lancet. Oncology.

[238]  M. Ratain,et al.  Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans , 2009, The Pharmacogenomics Journal.

[239]  D. Hochstrasser,et al.  The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction , 2009, The Pharmacogenomics Journal.

[240]  S. Oka,et al.  Successful genotype-tailored treatment with small-dose efavirenz. , 2009, AIDS.

[241]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[242]  F. Chiafari,et al.  DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping , 2009, CNS Spectrums.

[243]  A. Hofman,et al.  Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β‐Blocker Users , 2009, Clinical pharmacology and therapeutics.

[244]  B. Carleton,et al.  Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study , 2009, Clinical pharmacology and therapeutics.

[245]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[246]  Tongbin Li,et al.  miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..

[247]  R. Tyndale,et al.  Molecular genetics of nicotine metabolism. , 2009, Handbook of experimental pharmacology.

[248]  M. Ingelman-Sundberg,et al.  Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment , 2009, Human Genetics.

[249]  M. Ingelman-Sundberg,et al.  CNVs of human genes and their implication in pharmacogenetics , 2009, Cytogenetic and Genome Research.

[250]  D. Nebert,et al.  Endogenous Functions of the Aryl Hydrocarbon Receptor (AHR): Intersection of Cytochrome P450 1 (CYP1)-metabolized Eicosanoids and AHR Biology* , 2008, Journal of Biological Chemistry.

[251]  Masahiro Hiratsuka,et al.  Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57) , 2008, Drug Metabolism and Disposition.

[252]  R. Albano,et al.  CYP2A6 polymorphisms and risk for tobacco-related cancers. , 2008, Pharmacogenomics.

[253]  K. Yoshinari,et al.  Role of Vitamin D Receptor in the Lithocholic Acid-Mediated CYP3A Induction in Vitro and in Vivo , 2008, Drug Metabolism and Disposition.

[254]  K. Kidd,et al.  Global patterns of variation in allele and haplotype frequencies and linkage disequilibrium across the CYP2E1 gene , 2008, The Pharmacogenomics Journal.

[255]  Namandjé N. Bumpus,et al.  Investigation of the Mechanisms Underlying the Differential Effects of the K262R Mutation of P450 2B6 on Catalytic Activity , 2008, Molecular Pharmacology.

[256]  J. Aberg,et al.  Clinical impact of patient population differences and genomic variation in efavirenz therapy , 2008, AIDS.

[257]  M. Gawaz,et al.  CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. , 2008, Pharmacogenomics.

[258]  M. Ingelman-Sundberg,et al.  Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme , 2008, Human mutation.

[259]  M. Schwab,et al.  Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation , 2008, Analytical and bioanalytical chemistry.

[260]  S. Marsh,et al.  Developmental Changes in Human Liver CYP2D6 Expression , 2008, Drug Metabolism and Disposition.

[261]  J. Schenkman,et al.  Characterization of the biochemical and structural phenotypes of four CYP1B1 mutations observed in individuals with primary congenital glaucoma , 2008, Pharmacogenetics and genomics.

[262]  Eun-Young Kim,et al.  Genetic polymorphism of hepatocyte nuclear factor‐4α influences human cytochrome P450 2D6 activity , 2008, Hepatology.

[263]  M. Ingelman-Sundberg,et al.  Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism , 2008, The Pharmacogenomics Journal.

[264]  M. Ingelman-Sundberg,et al.  Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects , 2008, European Journal of Clinical Pharmacology.

[265]  B. Masters,et al.  Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. , 2008, Archives of biochemistry and biophysics.

[266]  K. Yoshinari,et al.  Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. , 2008, Biochemical pharmacology.

[267]  U. Hofmann,et al.  Propafenone for the Prevention of Atrial Tachyarrhythmias After Cardiac Surgery: A Randomized, Double‐blind Placebo‐controlled Trial , 2008, Clinical pharmacology and therapeutics.

[268]  J. Nieman,et al.  Bioactivation of Flutamide Metabolites by Human Liver Microsomes , 2008, Drug Metabolism and Disposition.

[269]  U. Zanger.  Chapter 8:The CYP2D Subfamily , 2008 .

[270]  Sang Chung,et al.  New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process , 2008, Journal of clinical pharmacology.

[271]  M. Rieder,et al.  Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression , 2008, Molecular Pharmacology.

[272]  H. Yamazaki,et al.  Heterotropic cooperativity in oxidation mediated by cytochrome p450. , 2008, Current drug metabolism.

[273]  R. Asinger,et al.  Characteristics of the amiodarone-warfarin interaction during long-term follow-up. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[274]  A. Gunes,et al.  Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. , 2008, Pharmacogenomics.

[275]  Kazuhiro Araki,et al.  CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1 , 2008, Cancer science.

[276]  M. Ingelman-Sundberg,et al.  Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. , 2008, British journal of clinical pharmacology.

[277]  John D. Storey,et al.  Mapping the Genetic Architecture of Gene Expression in Human Liver , 2008, PLoS biology.

[278]  Shingo Takagi,et al.  Post-transcriptional Regulation of Human Pregnane X Receptor by Micro-RNA Affects the Expression of Cytochrome P450 3A4* , 2008, Journal of Biological Chemistry.

[279]  M. Schwab,et al.  Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver , 2008, Journal of Pharmacology and Experimental Therapeutics.

[280]  Marie-Anne Loriot,et al.  Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. , 2008, Biochimie.

[281]  A. Cederbaum,et al.  CYP2E1 and oxidative liver injury by alcohol. , 2008, Free radical biology & medicine.

[282]  Kathleen M. Giacomini,et al.  Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations , 2008, Proceedings of the National Academy of Sciences.

[283]  Zhongqiu Wang,et al.  CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. , 2008, Lung cancer.

[284]  Z. Dvořák,et al.  Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. , 2008, Current drug metabolism.

[285]  V. Vasiliou,et al.  Role of CYP1B1 in glaucoma. , 2008, Annual review of pharmacology and toxicology.

[286]  A. Telenti,et al.  Pharmacogenetics of anti-HIV drugs. , 2008, Annual review of pharmacology and toxicology.

[287]  J. Pascussi,et al.  The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. , 2008, Annual review of pharmacology and toxicology.

[288]  Steven N Hart,et al.  Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism , 2008, Pharmacogenetics and genomics.

[289]  P. Neuvonen,et al.  Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone , 2008, Drug Metabolism and Disposition.

[290]  S. Strom,et al.  Novel Single Nucleotide Polymorphisms in the Promoter and Intron 1 of Human Pregnane X Receptor/NR1I2 and Their Association with CYP3A4 Expression , 2008, Drug Metabolism and Disposition.

[291]  J. Pascussi,et al.  Dexamethasone-Mediated Up-Regulation of Human CYP2A6 Involves the Glucocorticoid Receptor and Increased Binding of Hepatic Nuclear Factor 4α to the Proximal Promoter , 2007, Molecular Pharmacology.

[292]  W. Tan,et al.  Expression of cytochrome P4502E1 in human liver: Relationship between genotype and phenotype in Chinese , 2001, Science in China Series C: Life Sciences.

[293]  U. Zanger,et al.  Polymorphic Cytochromes P450 CYP2B6 and CYP2D6 : Recent Advances on Single Nucleotide Polymorphisms Affecting Splicing , 2008 .

[294]  A. Rostami-Hodjegan,et al.  CYP2D6 is primarily responsible for the metabolism of clomiphene. , 2008, Drug metabolism and pharmacokinetics.

[295]  B. Ring,et al.  In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine , 2008, Clinical pharmacokinetics.

[296]  Stefan Willmann,et al.  Physiology-Based Simulations of a Pathological Condition , 2008, Clinical pharmacokinetics.

[297]  E. Hodgson,et al.  Enzyme Induction and Cytotoxicity in Human Hepatocytes by Chlorpyrifos and N,N-Diethyl-m-toluamide (DEET) , 2008, Drug metabolism and drug interactions.

[298]  Fu-jun Liu,et al.  The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha. , 2008, The Biochemical journal.

[299]  F. Guengerich.  Cytochrome p450 and chemical toxicology. , 2008, Chemical research in toxicology.

[300]  Prosper Chonzi,et al.  High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe , 2008, European Journal of Clinical Pharmacology.

[301]  D. Banerjee,et al.  Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. , 2007, Pharmacogenomics.

[302]  Wolfgang Simon,et al.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[303]  S. Strom,et al.  Regulation of CYP3A4 and CYP2B6 expression by liver X receptor agonists. , 2007, Biochemical pharmacology.

[304]  R. Tyndale,et al.  Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. , 2007, Pharmacogenomics.

[305]  S. Matsushita,et al.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[306]  L. Bertilsson.  Metabolism of Antidepressant and Neuroleptic Drugs by Cytochrome P450s: Clinical and Interethnic Aspects , 2007, Clinical pharmacology and therapeutics.

[307]  Lang Li,et al.  Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects , 2007, Clinical pharmacology and therapeutics.

[308]  S. Kyo,et al.  Human CYP2A6 Is Induced by Estrogen via Estrogen Receptor , 2007, Drug Metabolism and Disposition.

[309]  A. El-Sohemy,et al.  Coffee, CYP1A2 genotype, and risk of myocardial infarction. , 2006, JAMA.

[310]  M. Eichelbaum,et al.  Selective Induction of Human Hepatic Cytochromes P450 2B6 and 3A4 by Metamizole , 2007, Clinical pharmacology and therapeutics.

[311]  P. Beaune,et al.  Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues , 2007, Pharmacogenetics and genomics.

[312]  P. Zimmerman,et al.  CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. , 2007, British journal of clinical pharmacology.

[313]  J. Hakkola,et al.  Transcription Factor Binding to a Putative Double E-Box Motif Represses CYP3A4 Expression in Human Lung Cells , 2007, Molecular Pharmacology.

[314]  Edward T. Morgan,et al.  Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes , 2007, Drug Metabolism and Disposition.

[315]  D. Mansuy,et al.  Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. , 2007, Archives of biochemistry and biophysics.

[316]  D. Banerjee,et al.  A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance , 2007, Proceedings of the National Academy of Sciences.

[317]  D. Moore,et al.  Alterations in xenobiotic metabolism in the long‐lived Little mice , 2007, Aging cell.

[318]  P. Rosenthal,et al.  Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa , 2007, Clinical pharmacology and therapeutics.

[319]  D. Seripa,et al.  Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. , 2007, Gastroenterology.

[320]  P. Beaune,et al.  Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. , 2007, Pharmacogenomics.

[321]  M. Schwab,et al.  Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. , 2007, Pharmacogenomics.

[322]  J. Schwartz.  The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology , 2007, Clinical pharmacology and therapeutics.

[323]  R. Finn,et al.  Conditional Deletion of Cytochrome P450 Oxidoreductase in the Liver and Gastrointestinal Tract: A New Model for Studying the Functions of the P450 System , 2007, Journal of Pharmacology and Experimental Therapeutics.

[324]  Lang Li,et al.  Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. , 2007, Pharmacogenomics.

[325]  M. Eichelbaum,et al.  Molecular Mechanism of Basal CYP3A4 Regulation by Hepatocyte Nuclear Factor 4α: Evidence for Direct Regulation in the Intestine , 2007, Drug Metabolism and Disposition.

[326]  H. Mukai,et al.  Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients , 2007, Pharmacogenetics and genomics.

[327]  C David Stout,et al.  Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦ , 2007, Journal of Biological Chemistry.

[328]  P. Carrupt,et al.  Stereoselective Block of hERG Channel by (S)‐Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers , 2007, Clinical pharmacology and therapeutics.

[329]  W. Haefeli,et al.  CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir , 2007, Clinical pharmacology and therapeutics.

[330]  P. Nürnberg,et al.  Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. , 2007, Pharmacogenomics.

[331]  M Schwab,et al.  Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals , 2007, Clinical pharmacology and therapeutics.

[332]  G. Kearns,et al.  Ontogeny of Dextromethorphan O‐ and N‐demethylation in the First Year of Life , 2007, Clinical pharmacology and therapeutics.

[333]  J. Goldstein,et al.  Detection of Human CYP2C8, CYP2C9, and CYP2J2 in Cardiovascular Tissues , 2007, Drug Metabolism and Disposition.

[334]  M. Kodaira,et al.  Pharmacogenomics‐based Tailored Versus Standard Therapeutic Regimen for Eradication of H. pylori , 2007, Clinical pharmacology and therapeutics.

[335]  H. McLeod,et al.  A Novel Duplication Type of CYP2A6 Gene in African-American Population , 2007, Drug Metabolism and Disposition.

[336]  M. Ingelman-Sundberg,et al.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans , 2007, European Journal of Clinical Pharmacology.

[337]  M. Negishi,et al.  CAR and PXR: The xenobiotic-sensing receptors , 2007, Steroids.

[338]  V. Natarajan,et al.  Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda , 2007, HIV medicine.

[339]  U. Fuhr,et al.  Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the “Cocktail” Approach , 2007, Clinical pharmacology and therapeutics.

[340]  E. Lobenhofer,et al.  Hepatic Transcript Levels for Genes Coding for Enzymes Associated with Xenobiotic Metabolism are Altered with Age , 2007, Toxicologic pathology.

[341]  E. Hodgson,et al.  The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. , 2007, Pharmacology & therapeutics.

[342]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[343]  Jiunn H Lin,et al.  Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. , 2007, Current drug metabolism.

[344]  Yi-Tong Liu,et al.  Drugs as CYP3A Probes, Inducers, and Inhibitors , 2007, Drug metabolism reviews.

[345]  Hongbing Wang,et al.  Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.

[346]  F. Gonzalez.  CYP2E1 , 2006, Drug Metabolism and Disposition.

[347]  C. Adithan,et al.  The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. , 2007, Current clinical pharmacology.

[348]  U. Klotz.  Antiarrhythmics: elimination and dosage considerations in hepatic impairment. , 2007, Clinical pharmacokinetics.

[349]  R. Novak,et al.  The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. , 2007, Pharmacology & therapeutics.

[350]  D. Seripa,et al.  enetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug – Related astroduodenal Bleeding : Role of Cytochrome P 450 2 C 9 Polymorphisms , 2007 .

[351]  U. Fuhr,et al.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping , 2007, European Journal of Clinical Pharmacology.

[352]  K. Brøsen,et al.  The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. , 2006, British journal of clinical pharmacology.

[353]  U. Fuhr,et al.  Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype , 2006, Clinical pharmacology and therapeutics.

[354]  D. Nebert,et al.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis , 2006, Nature Reviews Cancer.

[355]  M. Nakajima,et al.  Induction of Human CYP2A6 Is Mediated by the Pregnane X Receptor with Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α , 2006, Journal of Pharmacology and Experimental Therapeutics.

[356]  D. Zeldin,et al.  Variability of CYP2J2 Expression in Human Fetal Tissues , 2006, Journal of Pharmacology and Experimental Therapeutics.

[357]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[358]  N. Benowitz,et al.  Determinants of the rate of nicotine metabolism and effects on smoking behavior , 2006, Clinical pharmacology and therapeutics.

[359]  M. Eichelbaum,et al.  Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events , 2006, Pharmacogenetics and genomics.

[360]  Shingo Takagi,et al.  MicroRNA regulates the expression of human cytochrome P450 1B1. , 2006, Cancer research.

[361]  H. McLeod,et al.  Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations , 2006, Clinical pharmacology and therapeutics.

[362]  Gideon Koren,et al.  Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother , 2006, The Lancet.

[363]  T. Starzynska,et al.  Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients , 2006, European Journal of Clinical Pharmacology.

[364]  W. Miller,et al.  P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia , 2006, Current opinion in pediatrics.

[365]  D. Roden,et al.  Pharmacogenetics of antiarrhythmic therapy , 2006, Expert opinion on pharmacotherapy.

[366]  Luke O Dannenberg,et al.  Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation , 2006, BMC Genomics.

[367]  U. Klotz.  Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. , 2006, International journal of clinical pharmacology and therapeutics.

[368]  Namandjé N. Bumpus,et al.  Metabolism of Efavirenz and 8-Hydroxyefavirenz by P450 2B6 Leads to Inactivation by Two Distinct Mechanisms , 2006, Journal of Pharmacology and Experimental Therapeutics.

[369]  P. A. Ladd,et al.  Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells. , 2006, Toxicology and applied pharmacology.

[370]  Kaoru Kobayashi,et al.  INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4α IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER , 2006, Drug Metabolism and Disposition.

[371]  F. Gonzalez,et al.  A Common Regulatory Region Functions Bidirectionally in Transcriptional Activation of the Human CYP1A1 and CYP1A2 Genes , 2006, Molecular Pharmacology.

[372]  C. Smith,et al.  Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X Receptor , 2006, Journal of Pharmacology and Experimental Therapeutics.

[373]  Christina N. Lessov-Schlaggar,et al.  Female sex and oral contraceptive use accelerate nicotine metabolism , 2006, Clinical pharmacology and therapeutics.

[374]  J. Stevens.  New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. , 2006, Drug discovery today.

[375]  Mary F Paine,et al.  THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.

[376]  Li Jin,et al.  Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype , 2006, Pharmacogenetics and genomics.

[377]  P. Neuvonen,et al.  Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine , 2006, European Journal of Clinical Pharmacology.

[378]  R. Tyndale,et al.  Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine , 2006, Neuropharmacology.

[379]  C. Jepson,et al.  Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy , 2006, Molecular Psychiatry.

[380]  Bu Hz,et al.  A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. , 2006 .

[381]  J. Brockmöller,et al.  Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. , 2006, Chemical research in toxicology.

[382]  Makiko Maeda,et al.  CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation , 2006, The Pharmacogenomics Journal.

[383]  B. Roe,et al.  Sequence diversity and haplotype structure at the human CYP3A cluster , 2006, The Pharmacogenomics Journal.

[384]  Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction. , 2006, Canadian journal of physiology and pharmacology.

[385]  E. Spina,et al.  No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population. , 2006, Pharmacological research.

[386]  R. V. van Schaik,et al.  Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. , 2006, British journal of clinical pharmacology.

[387]  K. Tashima,et al.  Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[388]  T. A. Richardson,et al.  Regulation of drug-metabolizing enzymes and transporters in inflammation. , 2006, Annual review of pharmacology and toxicology.

[389]  M. Shimizu,et al.  Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[390]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[391]  A. D. Rodrigues,et al.  GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS , 2006, Drug Metabolism and Disposition.

[392]  Frank E. Blaney,et al.  Crystal Structure of Human Cytochrome P450 2D6* , 2005, Journal of Biological Chemistry.

[393]  H-Z Bu,et al.  A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. , 2006, Current drug metabolism.

[394]  A. Daly.  Significance of the Minor Cytochrome P450 3A Isoforms , 2006, Clinical pharmacokinetics.

[395]  M. Nakajima,et al.  Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. , 2006, The Journal of pharmacology and experimental therapeutics.

[396]  E. Kimby,et al.  Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[397]  A. Cederbaum.  CYP2E1--biochemical and toxicological aspects and role in alcohol-induced liver injury. , 2006, The Mount Sinai journal of medicine, New York.

[398]  D. Nelson,et al.  Cytochrome P450 nomenclature, 2004. , 2006, Methods in molecular biology.

[399]  M. Hopkins,et al.  The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies , 2006, The Pharmacogenomics Journal.

[400]  David A. Flockhart,et al.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.

[401]  M. Ingelman-Sundberg,et al.  Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. , 2005, Biochemical and biophysical research communications.

[402]  M. Eichelbaum,et al.  Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz , 2005, Pharmacogenetics and genomics.

[403]  C. Eap,et al.  Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment , 2005, Clinical pharmacology and therapeutics.

[404]  T. Fukami,et al.  CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS , 2005, Drug Metabolism and Disposition.

[405]  Sharon Marsh,et al.  Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel , 2005, Clinical Cancer Research.

[406]  A. Gaedigk,et al.  CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? , 2005, Biochemical and biophysical research communications.

[407]  M. Eichelbaum,et al.  Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study , 2005, Clinical pharmacology and therapeutics.

[408]  M. Haberl,et al.  Three haplotypes associated with CYP2A6 phenotypes in Caucasians , 2005, Pharmacogenetics and genomics.

[409]  M. Ingelman-Sundberg,et al.  CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele , 2005, Pharmacogenetics and genomics.

[410]  A. Gaedigk,et al.  Variability of CYP3A7 Expression in Human Fetal Liver , 2005, Journal of Pharmacology and Experimental Therapeutics.

[411]  E. Schuetz,et al.  Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. , 2005, Current drug metabolism.

[412]  J. Brockmöller,et al.  Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. , 2005, British journal of clinical pharmacology.

[413]  Michel Roger,et al.  CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS , 2005, Drug Metabolism and Disposition.

[414]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[415]  Namandjé N. Bumpus,et al.  THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION , 2005, Drug Metabolism and Disposition.

[416]  C. Martinez-Jimenez,et al.  Transcriptional Regulation of the Human Hepatic CYP3A4: Identification of a New Distal Enhancer Region Responsive to CCAAT/Enhancer-Binding Protein β Isoforms (Liver Activating Protein and Liver Inhibitory Protein) , 2005, Molecular Pharmacology.

[417]  Oliver Burk,et al.  Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1 Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane Receptor , 2005, Molecular Pharmacology.

[418]  M. Eichelbaum,et al.  A Natural CYP2B6 TATA Box Polymorphism (–82T→ C) Leading to Enhanced Transcription and Relocation of the Transcriptional Start Site , 2005, Molecular Pharmacology.

[419]  U. Hofmann,et al.  Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. , 2005, Clinical pharmacology and therapeutics.

[420]  Joseph Sack,et al.  Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. , 2005, American journal of human genetics.

[421]  Václav Martínek,et al.  Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. , 2005, Cancer letters.

[422]  I. Roots,et al.  Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. , 2005, Cancer research.

[423]  J. Ioannidis,et al.  CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis , 2005, Pharmacogenetics and genomics.

[424]  D. Nebert,et al.  Toward the evaluation of function in genetic variability: Characterizing human SNP frequencies and establishing BAC‐transgenic mice carrying the human CYP1A1_CYP1A2 locus , 2005, Human mutation.

[425]  H. Glaeser,et al.  Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. , 2005, British journal of clinical pharmacology.

[426]  S. Leucht,et al.  Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. , 2005, Clinical chemistry.

[427]  J. Hakkola,et al.  Regulation of CYP3A genes in the human respiratory tract. , 2005, Chemico-biological interactions.

[428]  D. Greenblatt,et al.  The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates , 2005, Clinical Pharmacokinetics.

[429]  J. Halpert,et al.  Structures of cytochrome P450 3A4. , 2005, Trends in biochemical sciences.

[430]  Jeffrey P. Jones,et al.  Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. , 2005, Annual review of pharmacology and toxicology.

[431]  M Ingelman-Sundberg,et al.  Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity , 2005, The Pharmacogenomics Journal.

[432]  G. Koren,et al.  Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity , 2005, Pediatric Nephrology.

[433]  Y. Daali,et al.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.

[434]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[435]  K. Kosaki,et al.  A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam , 2004, Brain and Development.

[436]  Felix W Frueh,et al.  From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. , 2004, Pharmacogenomics.

[437]  Kyoichi Ohashi,et al.  Pharmacogenomics of proton pump inhibitors. , 2004, Pharmacogenomics.

[438]  A. Weston,et al.  CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. , 2004, American journal of epidemiology.

[439]  K. Lindpaintner,et al.  Risk of Coronary Artery Disease Associated With Polymorphism of the Cytochrome P450 Epoxygenase CYP2J2 , 2004, Circulation.

[440]  U. Meyer,et al.  Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. , 2004, Pharmacogenetics.

[441]  A. El-Sohemy,et al.  Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction , 2004, Journal of Medical Genetics.

[442]  M. Eichelbaum,et al.  Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null Alleles , 2004, Journal of Pharmacology and Experimental Therapeutics.

[443]  J. Brockmöller,et al.  The Induction of Cytochrome P450 3A5 (CYP3A5) in the Human Liver and Intestine Is Mediated by the Xenobiotic Sensors Pregnane X Receptor (PXR) and Constitutively Activated Receptor (CAR)* , 2004, Journal of Biological Chemistry.

[444]  Ulrich Klotz,et al.  CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole‐based quadruple therapy for eradication of Helicobacter Pylori , 2004, Clinical pharmacology and therapeutics.

[445]  Urs A. Meyer,et al.  Pharmacogenetics – five decades of therapeutic lessons from genetic diversity , 2004, Nature Reviews Genetics.

[446]  M. Eichelbaum,et al.  A novel intronic mutation, 2988G>A, with high predictivity for impaired dunction of cytochrome P450 2D6 in white subjects , 2004, Clinical pharmacology and therapeutics.

[447]  J. Agúndez,et al.  Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms , 2004, Clinical pharmacology and therapeutics.

[448]  U. Klotz,et al.  CYP2C19 polymorphism and proton pump inhibitors. , 2004, Basic & clinical pharmacology & toxicology.

[449]  Allan B. Okey,et al.  Role of Aryl Hydrocarbon Receptor-mediated Induction of the CYP1 Enzymes in Environmental Toxicity and Cancer* , 2004, Journal of Biological Chemistry.

[450]  M. Ingelman-Sundberg,et al.  Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). , 2004, Pharmacogenetics.

[451]  R. Obach,et al.  Validated assays for human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[452]  Martin Widschwendter,et al.  Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.

[453]  Jose A G Agundez,et al.  Cytochrome P450 gene polymorphism and cancer. , 2004, Current drug metabolism.

[454]  J. Villeneuve,et al.  Cytochrome P450 and liver diseases. , 2004, Current drug metabolism.

[455]  M. Kinirons,et al.  Drug metabolism and ageing. , 2004, British journal of clinical pharmacology.

[456]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[457]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[458]  D. Greenblatt,et al.  Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. , 2004, Pharmacogenetics.

[459]  A. El-Kadi,et al.  The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. , 2004, Current drug metabolism.

[460]  A. Rettie,et al.  Developmental Expression of Human Hepatic CYP2C9 and CYP2C19 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[461]  P. Neuvonen,et al.  Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. , 2004, British journal of clinical pharmacology.

[462]  Oliver Burk,et al.  Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens , 2004, Clinical pharmacology and therapeutics.

[463]  Geraldine A Hamilton,et al.  Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[464]  H. Yamazaki,et al.  Identification of a novel polymorphic enhancer of the human CYP3A4 gene. , 2004, Molecular pharmacology.

[465]  F Peter Guengerich,et al.  Functional characterization of four allelic variants of human cytochrome P450 1A2. , 2004, Archives of biochemistry and biophysics.

[466]  E. Jabs,et al.  Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome , 2004, Nature Genetics.

[467]  A. Cederbaum,et al.  Oxidative stress, toxicology, and pharmacology of CYP2E1. , 2004, Annual review of pharmacology and toxicology.

[468]  M. Eichelbaum,et al.  Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.

[469]  L. Maltais,et al.  Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. , 2004, Pharmacogenetics.

[470]  R. Greenblatt,et al.  Sex differences in pharmacokinetics and pharmacodynamics. , 2004, Annual review of pharmacology and toxicology.

[471]  K. Brøsen.  Some aspects of genetic polymorphism in the biotransformation of antidepressants. , 2004, Therapie.

[472]  D. Lewis,et al.  Substrates of Human Cytochromes P4S0 from Families CYP1 and CYP2: Analysis of Enzyme Selectivity and Metabolism , 2004, Drug metabolism and drug interactions.

[473]  R. Preisig,et al.  Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man , 2004, European Journal of Clinical Pharmacology.

[474]  T. Nurminen,et al.  Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. , 2003, Cancer research.

[475]  B. Ring,et al.  Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.

[476]  M. Eichelbaum,et al.  CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real‐rime PCR , 2003, Human mutation.

[477]  Xinxin Ding,et al.  Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. , 2003, Annual review of pharmacology and toxicology.

[478]  R. Dhir,et al.  Interpulse growth hormone secretion in the episodic plasma profile causes the sex reversal of cytochrome P450s in senescent male rats , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[479]  N. Benowitz,et al.  Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism , 2003, Clinical pharmacology and therapeutics.

[480]  P. Neuvonen,et al.  Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide , 2003, Clinical pharmacology and therapeutics.

[481]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[482]  J. Sasse,et al.  Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. , 2003, Pharmacogenetics.

[483]  M. Fromm,et al.  Differential expression and function of CYP2C isoforms in human intestine and liver. , 2003, Pharmacogenetics.

[484]  C. Tickle,et al.  Identification of Novel Roles of the Cytochrome P450 System in Early Embryogenesis: Effects on Vasculogenesis and Retinoic Acid Homeostasis , 2003, Molecular and Cellular Biology.

[485]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[486]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[487]  H. Cui,et al.  Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene , 2003, Journal of Biological Chemistry.

[488]  D. Mash,et al.  Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.

[489]  J. Pascussi,et al.  Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. , 2003, Molecular pharmacology.

[490]  David A. Flockhart,et al.  The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[491]  M. Ingelman-Sundberg,et al.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[492]  W. Backes,et al.  Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes. , 2003, Pharmacology & therapeutics.

[493]  M. Ingelman-Sundberg,et al.  Transcriptional Regulation of Human CYP3A4 Basal Expression by CCAAT Enhancer-Binding Protein α and Hepatocyte Nuclear Factor-3γ , 2003 .

[494]  Hongbing Wang,et al.  A Novel Distal Enhancer Module Regulated by Pregnane X Receptor/Constitutive Androstane Receptor Is Essential for the Maximal Induction of CYP2B6 Gene Expression* , 2003, The Journal of Biological Chemistry.

[495]  S. Clarke,et al.  Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. , 2003, The Lancet. Oncology.

[496]  Ricarda Thier,et al.  The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine , 2003, International archives of occupational and environmental health.

[497]  L. S. Steijns,et al.  The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. , 2003, Pharmacogenetics.

[498]  Ai-Ming Yu,et al.  Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. , 2003, Pharmacogenetics.

[499]  J. Idle,et al.  The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine Tryptamine , 2003, Journal of Pharmacology and Experimental Therapeutics.

[500]  Wooin Lee,et al.  The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4 , 2003, Nature Medicine.

[501]  M. Ingelman-Sundberg,et al.  Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. , 2003, Molecular pharmacology.

[502]  M. Kitada.  Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. , 2003, International journal of clinical pharmacology research.

[503]  U. Yasar,et al.  Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.

[504]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[505]  S. Bandiera,et al.  Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[506]  P. Neuvonen,et al.  Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.

[507]  G. Mannens,et al.  CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. , 2002, Biochemical pharmacology.

[508]  J. Castell,et al.  Down‐regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[509]  Xiaoping Chen,et al.  Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. , 2002, British journal of clinical pharmacology.

[510]  T. Matsubara,et al.  Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[511]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[512]  J. Brockmöller,et al.  Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[513]  S. Kliewer,et al.  Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. , 2002, Molecular pharmacology.

[514]  Sharon Miksys,et al.  Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics , 2002, Journal of neurochemistry.

[515]  K. Kyvik,et al.  The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. , 2002, Pharmacogenetics.

[516]  M. Eichelbaum,et al.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. , 2002, British journal of clinical pharmacology.

[517]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[518]  H. Glaeser,et al.  Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine* , 2002, The Journal of Biological Chemistry.

[519]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[520]  G. Giles,et al.  The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. , 2002, Pharmacogenetics.

[521]  P. Wilson,et al.  Association Between the PPARA L162V Polymorphism and Plasma Lipid Levels: The Framingham Offspring Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[522]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[523]  H. Mohrenweiser,et al.  Cloning of CYP2J2 gene and identification of functional polymorphisms. , 2002, Molecular pharmacology.

[524]  M. Ingelman-Sundberg,et al.  Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. , 2002, Molecular pharmacology.

[525]  C. Kasper,et al.  Association of Multiple Developmental Defects and Embryonic Lethality with Loss of Microsomal NADPH-Cytochrome P450 Oxidoreductase* , 2002, The Journal of Biological Chemistry.

[526]  Tommy B Andersson,et al.  Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. , 2002, The Journal of pharmacology and experimental therapeutics.

[527]  M. Eichelbaum,et al.  Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. , 2002, Analytical Biochemistry.

[528]  M. Ingelman-Sundberg,et al.  The African‐specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity , 2002, Clinical pharmacology and therapeutics.

[529]  C. Meisner,et al.  Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism. , 2002, Pharmacogenetics.

[530]  A. Rosman,et al.  Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. , 2002, Journal of hepatology.

[531]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[532]  T. Adachi,et al.  Contribution of hepatocyte nuclear factor-4 to down-regulation of CYP2D6 gene expression by nitric oxide. , 2002, Molecular pharmacology.

[533]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[534]  J. Idle,et al.  The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. , 2001, Molecular pharmacology.

[535]  J. Schenkman,et al.  Effect of two mutations of human CYP1B1, G61E and R469W, on stability and endogenous steroid substrate metabolism. , 2001, Pharmacogenetics.

[536]  D. Nelson,et al.  Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. , 2001, Pharmacogenetics.

[537]  J. Goldstein,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.

[538]  J. Goldstein,et al.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. , 2001, Pharmacogenetics.

[539]  O Pelkonen,et al.  Polymorphisms of CYP2A6 and its practical consequences. , 2001, British journal of clinical pharmacology.

[540]  M Schwab,et al.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.

[541]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[542]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[543]  D. Yim,et al.  Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[544]  M. Eichelbaum,et al.  Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. , 2001, Pharmacogenetics.

[545]  W. F. Greenlee,et al.  Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. , 2001, Annual review of pharmacology and toxicology.

[546]  H. Yamazaki,et al.  Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[547]  C. Lindley,et al.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[548]  Jun-yan Hong,et al.  Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 2000, Cancer research.

[549]  A. Paterson,et al.  Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.

[550]  J. Witte,et al.  CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism , 2000, Clinical pharmacology and therapeutics.

[551]  C. Wolf,et al.  Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. , 2000, Pharmacogenetics.

[552]  K. Kreth,et al.  Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. , 2000, Biochemical pharmacology.

[553]  O. Pelkonen,et al.  CYP2A6: a human coumarin 7-hydroxylase. , 2000, Toxicology.

[554]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[555]  A. Gaedigk.  Interethnic differences of drug-metabolizing enzymes. , 2000, International journal of clinical pharmacology and therapeutics.

[556]  H. Zhou,et al.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. , 2000, British journal of clinical pharmacology.

[557]  C. Hiemke,et al.  Pharmacokinetics of selective serotonin reuptake inhibitors. , 2000, Pharmacology & therapeutics.

[558]  T. Kubota,et al.  Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele , 2000, European Journal of Clinical Pharmacology.

[559]  H Derendorf,et al.  Gender differences in pharmacokinetics and pharmacodynamics. , 1999, International journal of clinical pharmacology and therapeutics.

[560]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[561]  P. Beaune,et al.  Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.

[562]  J. Brockmöller,et al.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.

[563]  T. Kamataki,et al.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.

[564]  Paavo Honkakoski,et al.  The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene* , 1999, The Journal of Biological Chemistry.

[565]  J. Ward,et al.  Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[566]  Kiyoshi Inoue,et al.  Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes , 1999, Archives of Toxicology.

[567]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.

[568]  P. Gøtzsche,et al.  The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. , 1998, Pharmacogenetics.

[569]  D. G. McCarver,et al.  A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. , 1998, Toxicology and applied pharmacology.

[570]  M. Eichelbaum,et al.  Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation , 1998, Pain.

[571]  M. Eichelbaum,et al.  Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. , 1998, Pharmacogenetics.

[572]  T. Cresteil.  Onset of xenobiotic metabolism in children: toxicological implications. , 1998, Food additives and contaminants.

[573]  T. Rebbeck,et al.  More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.

[574]  S. Dehal,et al.  CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. , 1997, Cancer research.

[575]  J A McKay,et al.  Tumor-specific expression of cytochrome P450 CYP1B1. , 1997, Cancer research.

[576]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[577]  C. Lieber,et al.  Cytochrome P-4502E1: its physiological and pathological role. , 1997, Physiological reviews.

[578]  J. Sheller,et al.  Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. , 1997, The Journal of pharmacology and experimental therapeutics.

[579]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[580]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[581]  C. Wolf,et al.  Characterization of the Human Cytochrome P4502D6 Promoter , 1996, The Journal of Biological Chemistry.

[582]  U. Hofmann,et al.  Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4‐hydroxyantipyrine, 3‐hydroxymethylantipyrine, and norantipyrine formation , 1996, Clinical pharmacology and therapeutics.

[583]  T. Cresteil,et al.  Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. , 1996, European journal of biochemistry.

[584]  K. Tomer,et al.  Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in Heart (*) , 1996, The Journal of Biological Chemistry.

[585]  H. Yamazaki,et al.  Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[586]  R. Kim,et al.  Interindividual variability of chlorzoxazone 6‐hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms , 1995, Clinical pharmacology and therapeutics.

[587]  B. Lake,et al.  Expression and alternative splicing of the cytochrome P-450 CYP2A7. , 1995, The Biochemical journal.

[588]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[589]  D. Schrenk,et al.  The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. , 1994, Pharmacogenetics.

[590]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[591]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[592]  K. Brøsen,et al.  Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms , 1994, Clinical pharmacology and therapeutics.

[593]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[594]  G. F. Weber,et al.  Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. , 1993, Cancer research.

[595]  S. Wrighton,et al.  Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.

[596]  A. Rosman,et al.  Induction of cytochrome P‐4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA , 1993, Hepatology.

[597]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[598]  M. Relling,et al.  Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities , 1992, Clinical pharmacology and therapeutics.

[599]  U. Meyer,et al.  Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. , 1992, Genomics.

[600]  L. Bertilsson,et al.  Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype , 1990 .

[601]  R. Skoda,et al.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.

[602]  B. Dvorchik,et al.  Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[603]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[604]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.